Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Pfizer’s Ritlecitinib Earns CDE Breakthrough Designation for Ulcerative Colitis
The Center for Drug Evaluation (CDE) website indicates that Pfizer’s (NYSE: PFE) category 1 drug...
Ascletis Pharma Appoints John P. Gargiulo as Chief Business Officer to Lead Growth
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the appointment of Mr. John P. Gargiulo...
Beijing Winsunny Pharma Plans IPO to Boost Drug Development and Production
China-based Beijing Winsunny Pharmaceutical Co., Ltd. has announced plans for an initial public offering (IPO)...
Huadong Medicine’s SaiYueXin Receives NMPA Approval for Pediatric Psoriasis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...
Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful...
Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection
Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of...
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...
Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Latin America Accelerates COVID-19 Fight with Vaccine and Treatment Initiatives Across the Region
Latin America is ramping up its contributions to the worldwide race for COVID-19 vaccines and...
Exegenesis Bio Secures Multi-Million Dollar Series B Financing for Gene Therapy Pipeline
Exegenesis Bio Inc., a leading gene therapy company, has successfully completed a Series B financing...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...
Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription
Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in...
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico
Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...
Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...
Enhancing Clinical Trial Success: CDE’s New Adaptive Design Framework Opens for Comment
The newly proposed guidelines are designed to be applicable across a spectrum of confirmatory clinical...
Thermo Fisher Scientific Develops Serology Test to Detect COVID-19 Antibodies in Collaboration with WuXi Diagnostics and Mayo Clinic
Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...